Veracyte outlined plans to launch its TrueMRD minimal residual disease test in the first half of the year with an initial indication in muscle‑invasive bladder cancer and a pipeline across breast, lung, kidney and colorectal cancer. The company said it expects reimbursement at launch and aims to secure separate billing codes for baseline and surveillance. Complementing commercial moves, the BloodPAC consortium published JCO Precision Oncology protocols for analytically validating tumor‑informed ctDNA MRD assays, offering a harmonized framework for limit of detection, accuracy, precision, robustness and sample stability. Together the announcements advance both market readiness and analytical rigor for MRD testing.